Cancer Res Treat.  2019 Jul;51(3):886-900. 10.4143/crt.2018.375.

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer

Affiliations
  • 1Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. ohdoyoun@snu.ac.kr
  • 2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Abstract

PURPOSE
Jab1 is a coactivator of c-Jun that enhances the transcriptional function of c-Jun. Jab1 is frequently overexpressed in various cancers and is associatedwith poor prognosis of cancer patients. Thus, Jab1 could be a potential therapeutic target in cancer. However, the role of Jab1 in biliary tract cancer (BTC) has not been studied.
MATERIALS AND METHODS
We performed in vitro and in vivo experiments to evaluate the therapeutic potential ofJab1 inhibition in BTC.
RESULTS
Among 8 BTC cell lines, many showed higher Jab1 expression levels. In addition, Jab1 silencing by siRNA increased p27 expression levels. SNU478 and HuCCT-1 cells exhibited profound Jab1 knockdown and increased p27 expression by Jab1-specific siRNA transfection. Jab1 silencing induced anti-proliferative and anti-migratory effects and resulted in G1 cell cycle arrest in SNU478 and HuCCT-1 cells. In addition, Jab1 silencing potentiated the anti-proliferative and anti-migratory effects of cisplatin by increasing DNA damage. Interestingly,Jab1 knockdown increased PTEN protein half-life, resulting in increased PTEN expression. In the HuCCT-1 mouse xenograft model, stable knockdown of Jab1 by shRNA also showed anti-proliferative effects in vivo, with decreased Ki-67 expression and AKT phosphorylation and increased Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and p27 expression.
CONCLUSION
Jab1 knockdown demonstrated anti-proliferative and anti-migratory effects in BTC cells by increasing DNA damage and stabilizing PTEN, resulting in G1 cell cycle arrest. In addition, Jab1 silencing potentiated the anti-proliferative effects of cisplatin. Our data suggest that Jab1 may be a potential therapeutic target in BTC that is worthy of further investigations.

Keyword

Jab1; Biliary tract neoplasms; Proliferation; Therapeutic target; Cisplatin

MeSH Terms

Animals
Biliary Tract Neoplasms*
Biliary Tract*
Cell Line
Cisplatin*
DNA Damage
G1 Phase Cell Cycle Checkpoints
Half-Life
Heterografts
Humans
In Vitro Techniques
Mice
Phosphorylation
Prognosis
PTEN Phosphohydrolase
RNA, Small Interfering
Transfection
Cisplatin
PTEN Phosphohydrolase
RNA, Small Interfering

Figure

  • Fig. 1. Effects of Jab1 on p27 expression and cell proliferation in biliary tract cancer (BTC) cell lines. (A) Basal expression levels of Jab1 and p27 in eight BTC cell lines were analyzed by western blot and quantified by ImageJ software. (B) Effects of Jab1 silencing by siRNA on p27 expression were analyzed and quantified in eight BTC cell lines. (C) Knock-down effects of Jab1-specific siRNA were evaluated at 1 day, 3 days, and 5 days in SNU478 and HuCCT-1 cells. (D) MTT assays (upper) and colony forming assays (lower) were performed to evaluate the effects of Jab1 silencing on proliferation of SNU478 and HuCCT-1 cells. **p < 0.01.

  • Fig. 2. Effects of Jab1 silencing on cell cycle and migration. (A) Cell cycle analysis was performed in SNU478 and HuCCT1 cell lines after transfection with Jab1-specific or control siRNAs. **p < 0.01. (B) Cyclin D1/E/A expression levels were analyzed by western blot in SNU478 and HuCCT-1 cell lines transfected with Jab1-specific or control siRNA (C) Wound healing assays were performed to evaluate the effects of Jab1 silencing on migration in SNU478 and HuCCT-1 cell lines. *p < 0.05. (D) Transwell migration assays were performed to investigate the effects of Jab1 silencing on invasion of SNU478 and HuCCT-1 cells. **p < 0.01.

  • Fig. 3. Jab1 silencing and cisplatin sensitivity. (A) The effects of Jab1 silencing on the anti-proliferative activity of cisplatin at various concentrations were evaluated by colony formation assays in SNU478 and HuCCT-1 cells. Jab1-specific or control siRNA-transfected cells were treated with cisplatin at a concentration of 0, 0.5, 1.0, and 2.0 μM for 10 days. **p < 0.01. (B) Wound healing assays demonstrated the effects of Jab1 silencing on anti-migratory activity of cisplatin at a concentration of 0, 1.0, 2.5, and 5.0 μM. **p < 0.01. ***p < 0.001. (C) Comet assays were performed to quantify the effects of Jab1 silencing on DNA damage in SNU478 and HuCCT-1 cells. **p < 0.01.

  • Fig. 4. Effects of Jab1 on PTEN protein half-life. (A) The effects of Jab1 silencing on PTEN protein and mRNA expression levels were evaluated by western blot and real-time quantitative PCR in SNU478 and HuCCT-1 cells. N.S., not significant. The effects of Jab1 on Src and AKT and their phosphorylation (Src Tyr416 and AKT Ser473) were also analyzed by western blot. (B) In SNU478 and HuCCT-1 cell lines after transfection with Jab1-specific or control siRNA, PTEN protein expression levels were analyzed by western blot (upper) at 0, 1, 2, 6, and 24 hours of cycloheximide treatment. The band intensity (lower) was quantified using ImageJ software and normalized by β-actin expression levels.

  • Fig. 5. Stable knockdown of Jab1 by shRNA in HuCCT-1 cells. (A) Western blot analysis revealed the effects of stable knockdown of Jab1 by shRNA on p27 expression levels in HuCCT-1 cells. (B) MTT assays were performed to evaluate the effects of Jab1 knockdown on proliferation. (C) Wound healing assays demonstrated the anti-migratory effects of stable knockdown of Jab1 by shRNA in HuCCT-1 cells. **p < 0.01. (D) Using the HuCCT-1 mouse xenograft model, the effects of stable Jab1 silencing on proliferation were evaluated in vivo. **p < 0.01. (E) The tumors were harvested and analyzed by immunohistochemical staining of Jab1, Ki-67, and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling. (F) Western blot analysis evaluated the effects of Jab1 knockdown by shRNA on Jab1 and p27 expression, AKT and ERK phosphorylation, and cyclin D1 and A expression in vivo. The band intensity (lower) was quantified using ImageJ software and normalized by β-actin expression levels.


Reference

References

1. Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 1996; 383:453–7.
Article
2. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature. 1999; 398:160–5.
Article
3. Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, et al. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem. 2002; 277:2302–10.
Article
4. Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW, et al. Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J Biol Chem. 2006; 281:17457–65.
Article
5. Lee EW, Oh W, Song J. Jab1 as a mediator of nuclear export and cytoplasmic degradation of p53. Mol Cells. 2006; 22:133–40.
6. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, et al. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res. 2003; 9:5652–9.
7. Wang Y, Wang Y, Cheng C, Ji Y, Zhao Y, Zou L, et al. Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma. J Cancer Res Clin Oncol. 2009; 135:951–9.
Article
8. Wang Y, Yu YN, Song S, Li TJ, Xiang JY, Zhang H, et al. JAB1 and phospho-Ser10 p27 expression profile determine human hepatocellular carcinoma prognosis. J Cancer Res Clin Oncol. 2014; 140:969–78.
Article
9. Wang F, Wang Y, Yu X, Yang D, Wang Z, Lu C, et al. Significance of Jab1 expression in human esophageal squamous cell carcinoma. J Clin Gastroenterol. 2009; 43:520–6.
Article
10. Dong Y, Sui L, Watanabe Y, Yamaguchi F, Hatano N, Tokuda M. Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas. Clin Cancer Res. 2005; 11:259–66.
11. Shackleford TJ, Claret FX. JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div. 2010; 5:26.
Article
12. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009; 20:146–59.
Article
13. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362:1273–81.
Article
14. Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, et al. Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer. 2002; 87:187–93.
Article
15. Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, et al. Src as a therapeutic target in biliary tract cancer. Mol Cancer Ther. 2016; 15:1515–24.
Article
16. Jin MH, Nam AR, Park JE, Bang JH, Bang YJ, Oh DY. Resistance mechanism against trastuzumab in HER2-positive cancer cells and its negation by Src inhibition. Mol Cancer Ther. 2017; 16:1145–54.
Article
17. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011; 17:461–9.
Article
18. Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, et al. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene. 2010; 29:6125–37.
Article
19. Fukumoto A, Tomoda K, Yoneda-Kato N, Nakajima Y, Kato JY. Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. FEBS Lett. 2006; 580:5836–44.
Article
20. Schutz AK, Hennes T, Jumpertz S, Fuchs S, Bernhagen J. Role of CSN5/JAB1 in Wnt/beta-catenin activation in colorectal cancer cells. FEBS Lett. 2012; 586:1645–51.
21. Sang MM, Du WQ, Zhang RY, Zheng JN, Pei DS. Suppression of CSN5 promotes the apoptosis of gastric cancer cells through regulating p53-related apoptotic pathways. Bioorg Med Chem Lett. 2015; 25:2897–901.
Article
22. Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, et al. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 2012; 72:1890–900.
Article
23. Rivard N, L'Allemain G, Bartek J, Pouyssegur J. Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J Biol Chem. 1996; 271:18337–41.
24. Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene. 2013; 32:2756–66.
Article
25. Zhong G, Li H, Shan T, Zhang N. CSN5 silencing inhibits invasion and arrests cell cycle progression in human colorectal cancer SW480 and LS174T cells in vitro. Int J Clin Exp Pathol. 2015; 8:2809–15.
26. Hsu MC, Chang HC, Hung WC. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Endocr Relat Cancer. 2007; 14:655–67.
27. Hsu MC, Chai CY, Hou MF, Chang HC, Chen WT, Hung WC. Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu. Mod Pathol. 2008; 21:609–16.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr